Unraveling insulin-like growth factor binding protein-3 actions in human disease

Endocrine Reviews

Volumn 30, Issue 5, 2009, Pages 417-437

  Jogie Brahim, Sherryline ^a   Feldman, David ^b   Oh, Youngman ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN; GENOMIC DNA; GROWTH HORMONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; SERINE PROTEINASE; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

AMINO TERMINAL SEQUENCE; APOPTOSIS; AUTOCRINE EFFECT; BODY GROWTH; BREAST CANCER; CANCER CELL; CANCER RISK; CARBOXY TERMINAL SEQUENCE; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURFACE; COLORECTAL CANCER; DIABETES MELLITUS; HORMONE BINDING; HORMONE STRUCTURE; HUMAN; LUNG CANCER; MALNUTRITION; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; CELL DIFFERENTIATION; CELL NUCLEUS; CELL PROLIFERATION; CONSERVED SEQUENCE; GENE EXPRESSION; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; NEOPLASMS; POLYMORPHISM, GENETIC; PROTEIN BINDING; RECEPTOR, IGF TYPE 1; RECEPTORS, CELL SURFACE; RISK FACTORS; SOMATOMEDINS;

EID: 68549126809     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2008-0028     Document Type: Review

References (223)

1. Butler AA, Le Roith D 2001 Control of growth by the somatropic axis: growth hormone and the insulin-like growth factors have related and independent roles. Annu Rev Physiol 63:141-164
2. Stewart CE, Rotwein P 1996 Growth, differentiation and survival: multiple physiological functions of insulin-like growth factors. Physiol Rev 76:1005-1026
3. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, LeRoith D 1999 Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 96:7324-7329
4. Sjögren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, LeRoith D, Törnell J, Isaksson OG, Jansson JO, OhlssonC 1999 Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci USA 96:7088-7092
5. Siddle K, Ursø B, Niesler CA, Cope DL, Molina L, Surinya KH, Soos MA 2001 Specificity in ligand binding and intracellular signalling by insulin and insulin-like growth factor receptors. Biochem Soc Trans 29:513-525
6. Braulke T 1999 Type-2 IGF receptor: a multi-ligand binding protein. Horm Metab Res 31:242-246
7. Belfiore A 2007 The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 13:671-686
8. Walker GE, Kim HS, Yang YF, Oh Y 2004 IGF-independent effects of the IGFBP superfamily. In: Le Roith D, Zumkeller W, Baxter R, eds. Insulin-like growth factors. Austin, TX: Landes Bioscience; 1-22
9. Phillips LS, Pao CI, Villafuerte BC 1998 Molecular regulation of insulin-like growth factor-I and its principal binding protein, IGFBP-3. Prog Nucleic Acid Res Mol Biol 60: 195-265
10. Albiston AL, Saffery R, Herington AC 1995 Cloning and characterization of the promoter for the rat insulin-like growth factor-binding protein-3 gene. Endocrinology 136: 696-704
11. Olivecrona H, Hilding A, Ekström C, Barle H, Nyberg B, Möller C, Delhanty PJ, Baxter RC, Angelin B, EkströmTJ, TallyM1999 Acute and short-term effects of growth hormone on insulin-like growth factors and their binding proteins: serum levels and hepatic messenger ribonucleic acid responses in humans. J Clin Endocrinol Metab 84:553-560
12. Domené HM, Bengolea SV, Jasper HG, BoisclairYR 2005 Acid-labile subunit deficiency: phenotypic similarities and differences between human and mouse. J Endocrinol Invest 28(5 Suppl):43-46
13. HwaV,OhY, RosenfeldRG1999 The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 20:761-787
14. Zhu W, Shiojima I, Ito Y, Li Z, Ikeda H, Yoshida M, Naito AT, Nishi J, Ueno H, Umezawa A, Minamino T, Nagai T, Kikuchi A, Asashima M, Komuro I 2008 IGFBP-4 is an inhibitor of canonical Wnt signalling required for cardiogenesis. Nature 454:345-349
15. Perks CM, Newcomb PV, Norman MR, Holly JM 1999 Effect of insulin-like growth factor binding protein-1 on integrin signaling and the induction of apoptosis in human breast cancer cells. J Mol Endocrinol 22:141-150
16. Fu P, Thompson JA, Bach LA 2007 Promotion of cancer cell migration: an insulin-like growth factor (IGF)-independent action of IGF-binding protein-6. J Biol Chem 282: 22298-22306
17. Kiepe D, Van Der Pas A, Ciarmatori S, Ständker L, Schütt B, Hoeflich A, Hügel U, Oh J, Tönshoff B 2008 Defined carboxy-terminal fragments of insulin-like growth factor (IGF) binding protein-2 exert similar mitogenic activity on cultured rat growth plate chondrocytes as IGF-I. Endocrinology 149:4901-4911
18. Wetterau LA, Moore MG, Lee KW, Shim ML, Cohen P 1999 Novel aspects of the insulin-like growth factor binding proteins. Mol Genet Metab 68:161-181
19. Imai Y, Moralez A, Andag U, Clarke JB, Busby Jr WH, Clemmons DR 2000 Substitutions for hydrophobic amino acids in the N-terminal domains of IGFBP-3 and -5 markedly reduce IGF-1 binding and alter their biologic actions. J Biol Chem 275:18188-18194
20. Buckway CK, Wilson EM, Ahlsén M, Bang P, Oh Y, Rosenfeld RG 2001 Mutation of three critical amino acids of the N-terminal domain of IGFBP-3 essential for high affinity IGF binding. J Clin Endocrinol Metab 86:4943-4950
21. Lalou C, Lassarre C, Binoux M 1996 A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology 137:3206-3212
22. Salahifar H, Firth SM, Baxter RC, Martin JL 2000 Characterization of an amino-terminal fragment of insulin-like growth factor binding protein-3 and its effects in MCF-7 breast cancer cells. Growth Horm IGF Res 10:367-377
23. Firth SM, Baxter RC 2002 Cellular actions of the insulinlike growth factor binding proteins. Endocr Rev 23:824-854
24. Firth SM, Baxter RC 1999 Characterization of recombinant glycosylation variants of insulin-like growth factor binding protein-3. J Endocrinol 160:379-387
25. Yamanaka Y, Fowlkes JL, Wilson EM, Rosenfeld RG, Oh Y 1999 Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor domain on the IGFBP-3 molecule. Endocrinology 140:1319-1328
26. Spencer EM, Chan K 1995 A 3-dimensional model for the insulin-like growth factor binding proteins (IGFBPs); supporting evidence using the structural determinants of the IGF binding site on IGFBP-3. Prog Growth Factor Res 6:209-214
27. Ho PJ, Baxter RC 1997 Characterization of truncated insulin like growth factor binding protein-2 in human milk. Endocrinology 138:3811-3818
28. DeviGR,YangDH,RosenfeldRG,OhY2000 Differential effects of insulin-like growth factor (IGF)-binding protein-3 and its proteolytic fragments on ligand binding, cell surface association, and IGF-I receptor signaling. Endocrinology 141:4171-4179
29. Fowlkes JL, Serra DM 1996 Characterization of glycosaminoglycan- binding domains present in insulin-like growth factor binding protein-3. J Biol Chem 271:14676-14679
30. Smith EP, Lu L, Chernausek SD, Klein DJ 1994 Insulin-like growth factor binding protein-3 (IGFBP-3) concentration in rat Sertoli cell-conditioned medium is regulated by a pathway involving association of IGFBP-3 with cell surface proteoglycans. Endocrinology 135:359-364
31. Campbell PG, Durham SK, Hayes JD, Suwanichkul A, PowellDR1999 Insulin-like growth factor binding protein-3 binds fibrinogen and fibrin. J Biol Chem 274:30215-30221
32. Campbell PG, Durham SK, Suwanichkul A, Hayes JD, Powell DR 1998 Plasminogen binds the heparin-binding domain of insulin-like growth factor binding protein-3. Am J Physiol 275:E321-E331
33. Singh B, Charkowicz D, Mascarenhas D 2004 Insulin-like growth factor-independent effects mediated by a C-terminal metal-binding domain of insulin-like growth factor binding protein-3. J Biol Chem 279:477-487
34. Weinzimer SA, Gibson TB, Collett-Solberg PF, Khare A, Liu B, Cohen PJ 2001 Transferrin is an insulin-like growth factor-binding protein-3 binding protein. J Clin Endocrinol Metab 86:1806-1813
35. Kalus W, Zweckstetter M, Renner C, Sanchez Y, Georgescu J,GrolM,DemuthD,SchumacherR,DonyC,LangK,Holak TA1998 Structure of the IGF-binding domain of the insulinlike growth factor-binding protein-5 (IGFBP-5): implications for IGF and IGF-I receptor interactions. EMBO J 17:6558-6572
36. Fernández-Tornero C, Lozano RM, Rivas G, Jiménez MA, Ständker L, Díaz-Gonzalez D, Forssmann WG, Cuevas P, Romero A, Giménez-Gallego G 2005 Synthesis of the blood circulating C-terminal fragment of insulin-like growth factor (IGF)-binding protein-4 in its native conformation. Crystallization, heparin and IGF binding, and osteogenic activity. J Biol Chem 280:18899-18907
37. Sala A, Capaldi S, Campagnoli M, Faggion B, Labò S, Perduca M, Romano A, Carrizo ME, Valli M, Visai L, Minchiotti L, Galliano M, MonacoHL2005 Structure and properties of the C-terminal domain of insulin-like growth factor-binding protein-1 isolated from human amniotic fluid. J Biol Chem 280:29812-29819
38. Sitar T, Popowicz GM, Siwanowicz I, Huber R, Holak TA 2006 Structural basis for the inhibition of insulin-like growth factors by insulin-like growth factor-binding proteins. Proc Natl Acad Sci USA 103:13028-13033
39. Kuang Z, Yao S, McNeil KA, Thompson JA, Bach LA, Forbes BE, Wallace JC, Norton RS 2007 Cooperativity of the N-and C-terminal domains of insulin-like growth factor (IGF) binding protein 2 in IGF binding. Biochemistry 46:13720-13732
40. Rajaram S, Baylink DJ, Mohan S 1997 Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 18:801-831
41. Martin JL, Coverley JA, Pattison ST, Baxter RC 1995 Insulin-like growth factor-binding protein-3 production by MCF-7 breast cancer cells: stimulation by retinoic acid and cyclic adenosine monophosphate and differential effects of estradiol. Endocrinology 136:1219-1226
42. Oh Y, Müller HL, Lamson G, Rosenfeld RG 1993 Insulinlike growth factor (IGF)-independent action of IGFBP-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem 268:14964-14971
43. Rajah R, Valentinis B, Cohen P 1997 Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 272:12181-12188
44. Leal SM, Liu Q, Huang SS, Huang JS 1997 The type V transforming growth factor β receptor is the putative insulin-like growth factor-binding protein-3 receptor. J Biol Chem 272:20572-20576
45. Liu B, Lee HY, Weinzimer SA, Powell DR, Clifford JL, Kurie JM, Cohen P 2000 Direct functional interactions between insulin-like growth factor binding protein-3 and retinoidXreceptor αregulate transcriptional signaling and apoptosis. J Biol Chem 275:33607-33613
46. Schedlich LJ, Le Page SL, Firth SM, Briggs LJ, Jans DA, Baxter RC 2000 Nuclear import of insulin-like growth factor binding protein-3 and -5 is mediated by the importin γ subunit. J Biol Chem 275:23462-23470
47. Blat C, Delbe J, Villaudy J, Chatelain G, Golde A, Harel L 1989 Inhibitory diffusible factor 45 bifunctional activity. As a cell growth inhibitor and as an insulin-like growth factor I-binding protein. J Biol Chem 264:12449-12454
48. Liu L, Delbé J, Blat C, Zapf J, Harel L 1992 Insulin-like growth factor binding protein-3 (IGFBP-3), an inhibitor of serum growth factors other than IGF-I and -II. J Cell Physiol 153:15-21
49. Cohen P, Lamson G, Okajima T, Rosenfeld RG 1993 Transfection of the human insulin-like growth factor binding protein-3 gene into Balb/c fibroblasts inhibits cellular growth. Mol Endocrinol 7:380-386
50. Martin JL, Weenink SM, Baxter RC 2003 Insulin-like growth factor-binding protein-3 potentiates epidermal growth factor action in MCF-10A mammary epithelial cells. Involvement of p44/42 and p38 mitogen-activated protein kinases. J Biol Chem 278:2969-2976
51. Butt AJ, Martin JL, Dickson KA, McDougall F, Firth SM, Baxter RC 2004 Insulin-like growth factor binding protein-3 expression is associated with growth stimulation of T47D human breast cancer cells: the role of altered epidermal growth factor signaling. J Clin Endocrinol Metab 89:1950-1956
52. Granata R, Trovato L, Garbarino G, Taliano M, Ponti R, Sala G, Ghidoni R, Ghigo E 2004 Dual effects of IGFBP-3 on endothelial cell apoptosis and survival: involvement of the sphingolipid signaling pathways. FASEB J 18:1456-1458
53. Chang KH, Chan-Ling T, McFarland EL, Afzal A, Pan H, Baxter LC, Shaw LC, Caballero S, Sengupta N, Li Calzi S, Sullivan SM, Grant MB 2007 IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development. Proc Natl Acad Sci USA 104:10595-10600
54. Lofqvist C, Chen J, Connor KM, Smith AC, Aderman CM, Liu N, Pintar JE, Ludwig T, Hellstrom A, Smith LE 2007 IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proc Natl Acad Sci USA 104:10589-10594
55. Oh Y, Müller HL, Pham H, Rosenfeld RG 1993 Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J Biol Chem 268:26045-26048
56. ten Dijke P, Miyazono K, Heldin CH 1996 Signaling via hetero-oligomeric complexes of type I and type II serine/ threonine kinase receptors. Curr Opin Cell Biol 8:139-145
57. WuRY, Zhang Y, Feng XH, DerynckR1997 Heteromeric and homomeric interactions correlate with signaling activity and functional cooperativity of Smad 3 and Smad 4/DPC4. Mol Cell Biol 17:2521-2528
58. Lagna G, Hata A, Hemmati-Brivanlou A, Massagué J 1996 Partnership between DPC4 and SMAD proteins in TGF-β signaling pathways. Nature 383:832-836
59. Fanayan S, Firth SM, Butt AJ, Baxter RC 2000 Growth inhibition by insulin-like growth factor binding protein-3 in T47D breast cancer cells requires transforming growth factor-β (TGF-β) and the type II TGF-β receptor. J Biol Chem 275:39146-39151
60. Leal SM, Huang SS, Huang JS 1999 Interactions of high affinity insulin-like growth factor binding proteins with the typeVtransforming growth factor-βreceptor in mink lung epithelial cells. J Biol Chem 274:6711-6717
61. Huang SS, Ling TY, Tseng WF, Huang YH, Tang FM, Leal SM, Huang JS 2003 Cellular growth inhibition by IGFBP-3 and TGF-β I requires LRP-I. FASEB J 17:2068-2081
62. Butt AJ, Firth SM, King MA, Baxter RC 2000 Insulin-like growth factor binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiationinduced apoptosis in human breast cancer cells. J Biol Chem 275:39174-39181
63. Fowler CA, Perks CM, Newcomb PV, Savage PB, Farndon JR, Holly JM 2000 Insulin-like growth factor binding protein-3 potentiates paclitaxel-induced apoptosis in human breast cancer cells. Int J Cancer 88:448 -453
64. Fraser A, Evan G 1996 A license to kill. Cell 85:781-784
65. Li J, Yuan J 2008 Caspases in apoptosis and beyond. Oncogene 27:6194-6206
66. Kim HS, Ingermann AR, Tsubaki J, Twigg SM, Walker GE, Oh Y 2004 Insulin-like growth factor binding protein-3 induces caspase-dependent apoptosis through a death receptor-mediated pathway in MCF-7 human breast cancer cells. Cancer Res 64:2229-2237
67. Rajah R, LeeKW,Cohen P 2002 Insulin-like growth factor binding protein-3 mediates tumor necrosis factor-α-induced apoptosis: role of Bcl-2 phosphorylation. Cell Growth Differ 13:163-171
68. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, Sonenshein GE 1997 Aberrant nuclear factor-κB//Rel expression and the pathogenesis of breast cancer. J Clin Invest 100:2952-2960
69. Palayoor ST, YoumellMY,Calderwood SK, ColemanCN, Price BD 1999 Constitutive activation of IκB kinase α and NF-κB in prostate cancer cells in inhibited by ibuprofen. Oncogene 18:7389-7394
70. Baldwin Jr AS 1996 The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 14:649-683
71. Pahl HL 1999 Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18:6853-6866
72. KarinM1999 The beginning of the end: IκB kinase (IKK) and NF-κB activation. J Biol Chem 274:27339-27342
73. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, VermaIM 1996 Suppression of TNF-α-induced apoptosis by NF-κB. Science 274:787-789
74. Giri DK, AggarwalBB1998 Constitutive activation of NF-κκB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. J Biol Chem 273:14008-14014
75. Butt AJ, Dickson KA, Jambazov S, Baxter RC 2005 Enhancement of tumor necrosis factor-α-induced growth inhibition by insulin-like growth factor-binding protein-5 (IGFBP-5), but not IGFBP-3 in human breast cancer cells. Endocrinology 146:3113-3122
76. H-Zadeh AM, Collard TJ, Malik K, Hicks DJ, Paraskeva C, WilliamsAC2006 Induction of apoptosis by the 16-kDa amino-terminal fragment of the insulin-like growth factor binding protein 3 in human colonic carcinoma cells. Int J Oncol 29:1279-1286
77. Williams AC, Smartt H, H-Zadeh AM, Macfarlane M, Paraskeva C, Collard TJ 2007 Insulin-like growth factor binding protein 3 (IGFBP-3) potentiates TRAIL-induced apoptosis of human colorectal carcinoma cells through inhibition of NF-κB. Cell Death Differ 14:137-145
78. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet Jr RJ, Sledge Jr GW 1997 Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17:3629-3639
79. Wang CY, Cusack Jr JC, Liu R, Baldwin Jr AS 1999 Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 5:412-417
80. Fulda S, Debatin KM 2004 Targeting apoptosis pathways in cancer therapy. Curr Cancer Drug Targets 4:569-576
81. Kim BY, Kim KA, Kwon O, Kim SO, Kim MS, Kim BS, Oh WK, Kim GD, Jung M, Ahn JS 2005 NF-κB inhibition radiosensitizes Ki-Ras-transformed cells to ionizing radiation. Carcinogenesis 26:1395-1403
82. Mishra S, Murphy LJ 2003 Phosphorylation of insulin-like growth factor (IGF) binding protein-3 by breast cancer cell membranes enhances IGF-I binding. Endocrinology 144: 4042-4050
83. Mishra S, Murphy LJ 2004 Tissue transglutaminase has intrinsic kinase activity. Identification of transglutaminase 2 as an insulin-like growth factor binding protein-3 kinase. J Biol Chem 279:23863-23868
84. Mishra S, Raz A, Murphy LJ 2004 Insulin-like growth factor binding protein-3 interacts with autocrine motility factor/phosphoglucose isomerase (AMF/PGI) and inhibits the AMF/PGI function. Cancer Res 64:2516-2522
85. Schedlich LJ, Young TF, Firth SM, Baxter RC, 1998 Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. J Biol Chem 273: 18347-18352
86. Li W, Fawcett J, Widmer HR, Fielder PJ, Rabkin R, Keller GA 1997 Nuclear transport of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in opossum kidney cells. Endocrinology 138:1763-1766
87. JaquesG,Noll K,WegmannB, Witten S,KoganE, Radulescu RT, Havemann K 1997 Nuclear localization of insulin-like growth factor binding protein 3 in a lung cancer cell line. Endocrinology 138:1767-1770
88. Wraight CJ, Liepe IJ, White PJ, Hibbs AR, Werther GA 1998 Intranuclear localization of insulin-like growth factor binding protein-3 (IGFBP-3) during cell division in human keratinocytes. J Investig Dermatol 111:239-242
89. Radulescu RT 1994 Nuclear localization signal in insulinlike growth factor-binding protein type 3. Trends Biochem Sci 19:278
90. Schedlich LJ, O'Han MK, Leong GM, Baxter RC 2004 Insulin-like growth factor binding protein-3 prevents retinoid receptor heterodimerization: implications for retinoic acid-sensitivity in human breast cancer cells. Biochem Biophys Res Commun 314:83-88
91. Kastner P, Mark M, Chambon P 1995 Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? Cell 83:859-869
92. Mangelsdorf DJ, Evans RM 1995 The RXR heterodimers and orphan receptors. Cell 83:841-850
93. Hazel TG, Nathans D, Lau LF 1988 A gene inducible by serum growth factors encodes a member of the steroid and thyroid hormone receptor superfamily. Proc Natl Acad Sci USA 85:8444-8448
94. Zhang Y, Dawson MI, Mohammad R, Rishi AK, Farhana L, Feng KC, Leid M, Peterson V, Zhang XK, Edelstein M, Eilander D, Biggar S, Wall N, Reichert U, Fontana JA 2002 Induction of apoptosis of human B-CLL and ALL cells by a novel retinoid and its nonretinoidal analog. Blood 100: 2917-2925
95. Dawson MI, Hobbs PD, Peterson VJ, Leid M, Lange CW, Feng KC, Chen Gq, Gu J, Li H, Kolluri SK, Zhang Xk, Zhang Y, Fontana JA 2001 Apoptosis induction in cancer cells by a novel analogue of 6-[3-(1-adamantyl)-4- hydroxyphenyl]-2-naphthalenecarboxylic acid lacking retinoid receptor transcriptional activation activity. Cancer Res 61:4723-4730
96. Holmes WF, Soprano DR, Soprano KJ 2003 Comparison of the mechanism of induction of apoptosis in ovarian carcinoma cells by the conformationally restricted synthetic retinoids CD437 and 4-HPR. J Cell Biochem 89:262-278
97. Wu Q, Liu S, Ye XF, Huang ZW, Su WJ 2002 Dual roles of Nur77 in selective regulation of apoptosis and cell cycle by TPA and ATRA in gastric cancer cells. Carcinogenesis 23:1583-1592
98. Wilson AJ, Arango D, Mariadason JM, Heerdt BG, Augenlicht LH 2003 TR3/Nur77 in colon cancer cell apoptosis. Cancer Res 63:5401-5407
99. Li H, Kolluri SK, Gu J, Dawson MI, Cao X, Hobbs PD, Lin B, Chen G, Lu J, Lin F, Xie Z, Fontana JA, Reed JC, Zhang X 2000 Cytochrome C release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science 289:1159-1164
100. Forman BM, Umesono K, Chen J, EvansRM1995 Unique response pathways are established by allosteric interactions among nuclear hormone receptors. Cell 81:541-550
101. Lee KW, Ma L, Yan X, Liu B, Zhang XK, Cohen P 2005 Rapid apoptosis induction by IGFBP-3 involves an insulinlike growth factor-independent nucleomitochondrial translocation of RXRα/Nur77. J Biol Chem 280:16942-16948
102. Lee KW, Cobb LJ, Paharkova-Vatchkova V, Liu B, Milbrandt J, Cohen P 2007 Contribution of the orphan nuclear receptor Nur77 to the apoptotic action of IGFBP-3. Carcinogenesis 28:1653-1658
103. Cobb LJ, Liu B, Lee KW, Cohen P 2006 Phosphorylation by DNA-dependent protein kinase is critical for apoptosis induction by insulin-like growth factor binding protein-3. Cancer Res 66:10878-10884
104. Lee KW, Liu B, Ma L, Li H, Bang P, Koeffler HP, Cohen P 2004 Cellular Internalization of Insulin-like growth factor binding protein-3-distinct endocytic pathways facilitate re-uptake and nuclear localization. J Biol Chem 279: 469-476
105. Butt AJ, Fraley KA, Firth SM, BaxterRC 2002 Insulin-like growth factor binding protein-3-induced growth inhibition and apoptosis do not require cell-surface binding and nuclear translocation in human breast cancer cells. Endocrinology 143:2693-2699
106. Bhattacharyya N, Pechhold K, Shahjee H, Zappala G, Elbi C, Raaka B, Wiench M, Hong J, RechlerMM2006 Nonsecreted insulin-like growth factor binding protein-3 (IGFBP-3) can induce apoptosis in human prostate cancer cells by IGFindependent mechanisms without being concentrated in the nucleus. J Biol Chem 281:24588-24601
107. Zappala G, Elbi C, Edwards J, Gorenstein J, Rechler MM, Bhattacharyya N 2008 Induction of apoptosis in human prostate cancer cells by insulin-like growth factor binding protein-3 does not require binding to retinoid X receptor-α. Endocrinology 149:1802-1812
108. Liao L, Dearth RK, Zhou S, Britton OL, Lee AV,XuJ 2006 Liver-specific overexpression of the insulin-like growth factor-I enhances somatic growth and partially prevents the effects of growth hormone deficiency. Endocrinology 147:3877-3888
109. DiGirolamo DJ, Mukherjee A, Fulzele K, Gan Y, Cao X, Frank SJ, Clemens TL 2007 Mode of growth hormone action in osteoblasts. J Biol Chem 282:31666-31674
110. Blum WF 1996 Insulin-like growth factors and IGF-binding proteins: their use for diagnosis of growth hormone deficiency. In: Juul A, Jorgensen JOL, eds. Growth hormone in adults: physiological and clinical aspects. Cambridge, UK: Cambridge University Press; 48-74
111. Marzullo P,DiSommaC, PrattKL,Khosravi J,DiamandisA, Lombardi G, Colao A, Rosenfeld RG 2001 Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults. J Clin Endocrinol Metab 86:3001-3008
112. Arosio M, Garrone S, Bruzzi P, Faglia G, Minuto F, Barreca A 2001 Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3. J Clin Endocrinol Metab 86:1091-1098
113. OhY,Müller HL,NgL, RosenfeldRG1995 Transforming growth factor-β-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J Biol Chem 270:13589-13592
114. Gucev ZS, Oh Y, Kelley KM, Rosenfeld RG 1996 Insulinlike growth factor binding protein-3 mediates retinoic acid-and transforming growth factor β2-induced growth inhibition in human breast cancer cells. Cancer Res 56:1545-1550
115. Martin JL, Ballesteros M, Baxter RC 1992 Insulin-like growth factor-I (IGF-I) and transforming growth factor-β1 release IGF-binding protein-3 from human fibroblasts by different mechanisms. Endocrinology 131:1703-1710
116. Yateman ME, Claffey DC, Cwyfan Hughes SC, Frost VJ, Wass JA, Holly JM 1993 Cytokines modulate the sensitivity of human fibroblasts to stimulation with insulin-like growth factor-I (IGF-I) by altering endogenous IGF-binding protein production. J Endocrinol 137:151-159
117. Besset V, Le Magueresse-Battistoni B, Collette J, Benahmed M 1996 Tumor necrosis factor α stimulates insulin-like growth factor binding protein 3 expression in cultured porcine Sertoli cells. Endocrinology 137:296-303
118. Olney RC, Wilson DM, Mohtai M, Fielder PJ, Smith RL 1995 Interleukin-1 and tumor necrosis factor-α increase insulin-like growth factor binding protein-3 production and IGFBP-3 protease activity in human articular chondrocytes. J Endocrinol 146:279-286
119. Nickerson T,HuynhH1999 VitaminDanalogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins. J Endocrinol 160:223-229
120. Huynh H, Yang X, Pollak M 1996 Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 271:1016-1021
121. Nickerson T, Pollak M 1999 Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding protein. Urology 54:1120-1125
122. Boyle BJ, Zhao XY, Cohen P, FeldmanD2001 Insulin-like growth factor binding protein-3 mediates 1 α,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 165:1319-1324
123. Peng L, Malloy PJ, Feldman D 2004 Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol Endocrinol 18:1109-1119
124. Peng L, Malloy PJ, Wang J, Feldman D 2006 Growth inhibitory concentrations of androgens up-regulate insulinlike growth factor binding protein-3 expression via an androgen response element in LNCaP human prostate cancer cells. Endocrinology 147:4599-4607
125. Krishnan AV, Moreno J, Nonn L, Malloy P, Swami S, Peng L, Peehl DM, Feldman D 2007 Novel pathways that contribute to the antiproliferative and chemopreventive activities of calcitriol in prostate cancer. J Steroid Biochem Mol Biol 103:694-702
126. Zhao XY, Ly LH, Peehl DM, Feldman D 1997 1α,25- Dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology 138: 3290-3298
127. Peng L, Wang J, Malloy PJ, Feldman D 2008 The role of insulin-like growth factor binding protein-3 (IGFBP-3) in the growth inhibitory actions of androgens in LNCaP human prostate cancer cells. Int J Cancer 122:558-566
128. Sonnenschein C, Olea N, Pasanen ME, Soto AM 1989 Negative controls of cell proliferation: human prostate cancer cells and androgens. Cancer Res 49:3474-3481
129. Lee C, SutkowskiDM,Sensibar JA, Zelner D,KimI, Amsel I, Shaw N, Prins GS, Kozlowski JM 1995 Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 136:796-803
130. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, KleyN1995 Induction of the growth inhibitor IGF-binding protein-3 by p53. Nature 377:646-649
131. Bourdon JC, Deguin-Chambon V, Lelong JC, Dessen P, MayP, Debuire B,MayE 1997 Further characterization of the p53 responsive element-identification ofnewcandidate genes for trans-activation by p53. Oncogene 14:85-94
132. Grimberg A, Coleman CM, Burns TF, Himelstein BP, Koch CJ, Cohen P, El-Deiry WS 2005 P53-Dependent and p53-independent induction of insulin-like growth factor binding protein-3 by deoxyribonucleic acid damage and hypoxia. J Clin Endocrinol Metab 90:3568-3574
133. Yi HK, Kim SY, Hwang PH, Kim CY, Yang DH,OhY, Lee DY2005 Impact of PTEN on the expression of insulin-like growth factors (IGFs) and IGF binding proteins in human gastric adenocarcinoma cells. Biochem Biophys Res Commun 330:760-767
134. Yin Y, Ni J, ChenM,DiMaggioMA,GuoY, Yeh S 2007 The therapeutic and preventive effect of RRR-α-vitamin E succinate on prostate cancer via induction of insulin-like growth factor binding protein-3. Clin Cancer Res 13:2271-2280
135. Jenuwein T, Allis CD 2001 Translating the histone code. Science 293:1074-1080
136. Feinberg AP, Vogelstein B 1983 Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301:89-92
137. Jones PA, LairdPW1999 Cancer epigenetics comes of age. Nat Genet 21:163-167
138. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG 2001 Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 10:687-692
139. Esteller M, Corn PG, Baylin SB, Herman JG 2001 A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229
140. Herman JG, Baylin SB 2003 Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042-2054
141. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, Herman JG, Baylin SB 2002 A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 31:141-149
142. Baylin SB 2004 Reversal of gene silencing as a therapeutic target for cancer-roles for DNA methylation and its interdigitation with chromatin. Novartis Found Symp 259: 226-233; discussion 234-237, 285-288
143. Tomii K, Tsukuda K, Toyooka S, Dote H, Hanafusa T, Asano H, NaitouM,Doihara H, Kisimoto T, Katayama H, Pass HI, Date H, Shimizu N 2007 Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers. Int J Cancer 120:566-573
144. Wiley A, Katsaros D, Fracchioli S, YuH2006 Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. Int J Gynecol Cancer 16:210-218
145. Ibanez de Caceres I, Dulaimi E, Hoffman AM, Al-Saleem T, Uzzo RG, Cairns P 2006 Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res 66:5021-5028
146. Hanafusa T, Yumoto Y, Nouso K, Nakatsukasa H, Onishi T, Fujikawa T, Taniyama M, Nakamura S, Uemura M, Takuma Y, Yumoto E, Higashi T, Tsuji T 2002 Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett 176:149-158
147. Chang YS, Wang L, Liu D, Mao L, Hong WK, Khuri FR, LeeHY2002 Correlation between insulin-like growth factor binding protein-3 promoter methylation and prognosis of patients with Stage I non-small cell lung cancer. Clin Cancer Res 8:3669-3675
148. Chang YS, Wang L, Suh YA, Mao L, Karpen SJ, Khuri FR, Hong WK, Lee HY 2004 Mechanisms underlying lack of insulin-like growth factor binding protein-3 expression in non-small-cell lung cancer. Oncogene 23:6569-6580
149. Yamashita S, Tsujino Y, Moriguchi K, Tatematsu M, Ushijima T 2006 Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarrayed. Cancer Sci 97:64-71
150. Paquette J, Bessette B, Ledru E, DealC2007 Identification of
151. Gray SG, Kytola S, Lui WO, Larsson C, Ekstrom TJ 2000 Modulating IGFBP-3 expression by trichostatin A: potential therapeutic role in the treatment of hepatocellular carcinoma. Int J Mol Med 5:33-41
152. Walker GE, Wilson EM, Powell D, Oh Y 2001 Butyrate, a histone deacetylase inhibitor, activates the human IGF binding protein-3 promoter in breast cancer cells: molecular mechanism involves an Sp1/Sp3 multiprotein complex. Endocrinology 142:3817-3827
153. Tsubaki J, Choi WK, Ingermann AR, Twigg SM, Kim HS, Rosenfeld RG, Oh Y 2001 Effects of sodium butyrate on expression of members of the IGF-binding protein superfamily in human mammary epithelial cells. J Endocrinol 169:97-110
154. Thelen P, Schweyer S, Hemmerlein B, Wuttke W, Seseke F, Ringert RH 2004 Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells. Int J Oncol 24:25-31
155. Chun SY, Chen F, Washburn JG, MacDonald JW, Innes KL, Zhao R, Cruz-CorreaMR,Dang LH, DangDT2007CDX2 promotes anchorage-independent growth by transcriptional repression of IGFBP-3. Oncogene 26:4725-4729
156. Niwa H, Toyooka Y, Shimosato D, Strumpf D, Takahashi K, Yagi R, Rossant J 2005 Interaction between Oct3/4 and Cdx2 determines trophectoderm differentiation. Cell 123: 917-929
157. Irwin JC, Suen LF, Cheng BH, Martin R, Cannon P, Deal CL, Giudice LC 2000 Human placental trophoblasts secrete a disintegrin metalloproteinase very similar to the insulin-like growth factor binding protein-3 protease in human pregnancy serum. Endocrinology 141:666-674
158. Prieur A, Tirode F, Cohen P, Delattre O 2004 EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein-3. Mol Cell Biol 24:7275-7283
159. Benini S, Zuntini M, Manara MC, Cohen P, Nicoletti G, Nanni P, Oh Y, Picci P, Scotlandi K 2006 Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma. Int J Cancer 119:1039-1046
160. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG 1992 Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 75: 1046-1053
161. Cohen P, Peehl DM, Graves HC, Rosenfeld RG 1994 Biological effects of prostate specific antigen as an insulinlike growth factor binding protein-3 protease. J Endocrinol 142:407-415
162. Rajah R, Bhala A, Nunn SE, Peehl DM, Cohen P 1996 7S Nerve growth factor is an insulin-like growth factor binding protein protease. Endocrinology 137:2676-2682
163. Angelloz-Nicoud P, Harel L, BinouxM1996 Recombinant human insulin-like growth factor (IGF) binding protein-3 stimulates prostate carcinoma cell proliferation via an IGFindependent mechanism: role of serine proteases. Growth Regul 6:130-136
164. Sano A, Sangai T, Maeda H, Nakamura M, Hasebe T, Ochiai A 2007 Kallikrein 11 expressed in human breast cancer cells releases insulin-like growth factor through degradation of IGFBP-3. Int J Oncol 30:1493-1498
165. Gibson TL, Cohen P 1999 Inflammation-related neutrophil proteases, cathepsin G and elastase, function as insulin-like growth factor binding protein proteases. Growth Horm IGF Res 9:241-253
166. Claussen M, Kübler B, Wendland M, Neifer K, Schmidt B, Zapf J, Braulke T 1997 Proteolysis of insulin-like growth factors (IGF) and IGF binding proteins by cathepsin D. Endocrinology 138:3797-3803
167. Conover CA, De Leon DD 1994 Acid-activated insulinlike growth factor-binding protein-3 proteolysis in normal and transformed cells. Role of cathepsin D. J Biol Chem 269:7076-7080
168. Zwad O, Kübler B, Roth W, Scharf JG, Saftig P, Peters C, Braulke T 2002 Decreased intracellular degradation of insulin-like growth factor binding protein-3 in cathepsin L-deficient fibroblasts. FEBS Lett 510:211-215
169. Visse R, Nagase H 2003 Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92:827-839
170. LijnenHR2001 Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 86:324-333
171. Birkedal-Hansen H 1995 Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 7:728-735
172. Lynch CC, Matrisian LM 2002 Matrix metalloproteinases in tumor-host cell communication. Differentiation 70:561-573
173. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T 2003 Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253:269-285
174. Yu WH, Woessner Jr JF, McNeish JD, Stamenkovic I 2002 CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev 16:307-323
175. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, Leber TM, Mangan M, Miller K, Nayee P, Owen K, Patel S, Thomas W, Wells G, Wood LM, WoolleyK1994 Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 370:555-557
176. Hashimoto G, Inoki I, Fujii Y, Aoki T, Ikeda E, Okada Y 2002 Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J Biol Chem 277:36288-36295
177. Miyamoto S, Yano K, Sugimoto S, Ishii G, Hasebe T, Endoh Y, Kodama K, Goya M, Chiba T, Ochiai A 2004 Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. Cancer Res 64:665-671
178. Mochizuki S, Shimoda M, Shiomi T, Fujii Y, Okada Y 2004 ADAM28 is activated by MMP-7 (matrilysin-1) and cleaves insulin-like growth factor binding protein-3. Biochem Biophys Res Commun 315:79-84
179. Mitsui Y, Mochizuki S, Kodama T, Shimoda M, Ohtsuka T, Shiomi T, Chijiiwa M, Ikeda T, Kitajima M, Okada Y 2006 ADAM28 is overexpressed in human breast carcinomas: implications for carcinoma cell proliferation through cleavage of insulin-likegrowthfactor binding protein-3.Cancer Res 66:9913-9920
180. Grzmil M, Hemmerlein B, Thelen P, Schweyer S, Burfeind P 2004 Blockade of the type I IGF receptor expression in human prostate cancer cells inhibits proliferation and invasion, up-regulates IGF binding protein-3, and suppresses MMP-2 expression. J Pathol 202:50-59
181. Sadowski T, Dietrich S, Koschinsky F, Sedlacek R 2003 Matrix metalloproteinase 19 regulates insulin-like growth factor-mediated proliferation, migration, and adhesion in human keratinocytes through proteolysis of insulin-like growth factor binding protein-3. Mol Biol Cell 14:4569-4580
182. Rajah R, Nachajon RV, Collins MH, Hakonarson H, Grunstein MM, Cohen P 1999 Elevated levels of the IGF-binding protein protease MMP-1 in asthmatic airway smooth muscle. Am J Respir Cell Mol Biol 20:199 - 208
183. Fowlkes JL, Thrailkill KM, Serra DM, Suzuki K, Nagase H 1995Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. Prog Growth Factor Res 6:255-263
184. Ikonen M, Liu B, Hashimoto Y, Ma L, Lee KW, Niikura T, Nishimoto I, Cohen P 2003 Interaction between the Alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis. Proc Natl Acad Sci USA 100:13042-13047
185. Oufattole M, Lin SW, Liu B, Mascarenhas D, Cohen P, Rodgers BD 2006 Ribonucleic acid polymerase II binding subunit 3 (Rpb3), a potential nuclear target of insulin-like growth factor binding protein-3. Endocrinology 147:2138-2146
186. Wu C, Yao G, Zou M, Chen G, Wang M, Liu J, Wang J, XuD 2007 N-Acetylgalactosaminyltransferase 14, a novel insulin-like growth factor binding protein-3 binding partner. Biochem Biophys Res Commun 357:360-365
187. Grimberg A 2000 p53 and IGFBP-3: apoptosis and cancer protection. Mol Genet Metab 70:85-98 188. Sherr CJ 2004 Principles of tumor suppression. Cell 116: 235-246
188. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, PollakM1998 Plasma insulinlike growth factor-I and prostate cancer risk: a prospective study. Science 279:563-566
189. Wang L, Habuchi T, Tsuchiya N, Mitsumori K, Ohyama C, Sato K, Kinoshita H, Kamoto T, Nakamura A, Ogawa O, KatoT2003 Insulin-like growth factor-binding protein-3 gene -202A/C polymorphism is correlated with advanced disease status in prostate cancer. Cancer Res 63:4407-4411
190. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ 1999 Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor(IGF)-1 and IGF-binding protein-3. J Natl Cancer Inst 91:620 -625
191. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X 1999 Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91:151-156
192. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M 1998 Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393-1396
193. Toniolo P, Bruning PF, Akhmedkhanov A, Bonfrer JM, Koenig KL, Lukanova A, Shore RE, Zeleniuch-JacquotteA 2000 Serum insulin-like growth factor-I and breast cancer. Int J Cancer 88:828-832
194. Kaaks R, Lundin E, Rinaldi S, Manjer J, Biessy C, Söderberg S, Lenner P, Janzon L, Riboli E, Berglund G, Hallmans G 2002 Prospective study of IGF-I, IGF-binding proteins and breast cancer risk in northern and southern Sweden. Cancer Causes Control 13:307-316
195. Keinan-Boker L, Bueno De Mesquita HB, Kaaks R, Van Gils CH, Van Noord PA, Rinaldi S, Riboli E, Seidell JC, Grobbee DE, PeetersPH2003 Circulating levels of insulinlike growth factor I, its binding proteins -1, -2, -3Cpeptide and risk of postmenopausal breast cancer. Int J Cancer 106:90-95
196. Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE 2000 Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res 60:3744-3748
197. Becker S, Kaaks R 2009 Exogenous and endogenous hormones, mammographic density and breast cancer risk: can mammographic density be considered an intermediate marker of risk? Recent Results Cancer Res 181:135-157
198. Weiss JM, Huang WY, Rinaldi S, Fears TR, Chatterjee N, Chia D, Crawford ED, Kaaks R, HayesRB2007 IGF-1 and IGFBP-3: risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Int J Cancer 121:2267-2273
199. Allen NE, Key TJ, Appleby PN, Travis RC, Roddam AW, Rinaldi S, Egevad L, Rohrmann S, Linseisen J, Pischon T, Boeing H, Johnsen NF, Tjønneland A, Grønbaek H, Overvad K, Kiemeney L, Bueno-de-Mesquita HB, Bingham S, Khaw KT, Tumino R, Berrino F, Mattiello A, Sacerdote C, Palli D, Quirós JR, Ardanaz E, Navarro C, Larrañaga N, Gonzalez C, Sanchez MJ, Trichopoulou A, Travezea C, Trichopoulos D, Jenab M, Ferrari P, Riboli E, Kaaks R 2007 Serum insulin-like growth factor (IGF)-I and IGFEndocrine binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 16:1121-1127
200. Severi G, Morris HA, MacInnis RJ, English DR, Tilley WD, Hopper JL, Boyle P, Giles GG 2006 Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15:1137-1141
201. Chen C, Lewis SK, Voigt L, Fitzpatrick A, Plymate SR, Weiss NS 2005 Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer 103:76-84
202. Baglietto L, English DR, Hopper JL, Morris HA, Tilley WD, Giles GG 2007 Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 16:763-768
203. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M 2004 Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346-1353
204. Fletcher O, Gibson L, Johnson N, Altmann DR, Holly JM, Ashworth A, Peto J, Silva Idos S 2005 Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 14:2-19
205. Sugumar A, Liu YC, Xia Q, Koh YS, Matsuo K 2004 Insulinlike growth factor (IGF)-I and IGF-binding protein 3 and the risk of premenopausal breast cancer: a meta-analysis of literature. Int J Cancer 111:293-297
206. Rinaldi S, Peeters PH, Berrino F, Dossus L, Biessy C, Olsen A, Tjonneland A, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Téhard B, Nagel G, Linseisen J, Boeing H, Lahmann PH, Trichopoulou A, Trichopoulos D, Koliva M, Palli D, Panico S, Tumino R, Sacerdote C, van Gils CH, van Noord P, Grobbee DE, Bueno-de-Mesquita HB, Gonzalez CA, Agudo A, Chirlaque MD, Barricarte A, Larrañaga N, Quiros JR, Bingham S, Khaw KT, Key T, Allen NE, Lukanova A, Slimani N, Saracci R, Riboli E, Kaaks R 2006 IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 13:593-605
207. Friedrich N, Haring R, Nauck M, Lüdemann J, Rosskopf D, Spilcke-Liss E, Felix SB, Dörr M, Brabant G, Völzke H, Wallaschofski H 2009 Mortality and serum insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. J Clin Endocrinol Metab 94:1732-1739
208. Fuchs CS, Goldberg RM, Sargent DJ, Meyerhardt JA, Wolpin BM, Green EM, Pitot HC, Pollak M 2008 Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res 14:8263-8269
209. Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, Pollak MN, Giovannucci EL, Fuchs CS 2009 Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol 27:176-185
210. Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A, Hsing AW, Lacey JV Jr, Helzlsouer K, Rinaldi S, Riboli E, Kaaks R, Janssen JA, Wildhagen MF, Schröder FH, Platz EA, Pollak M, Giovannucci E, Schaefer C, QuesenberryCP Jr, Vogelman JH, Severi G, English DR, Giles GG, Stattin P, Hallmans G, Johansson M, Chan JM, Gann P, Oliver SE, Holly JM, Donovan J, Meyer F, Bairati I, Galan P 2008 Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 149:461-471, W83-W88
211. Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM 2009 Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 124:2416-2429
212. Neuhouser ML, Schenk J, Song YJ, Tangen CM, Goodman PJ, Pollak M, Penson DF, Thompson IM, Kristal AR 2008 Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. Prostate 68:1477-1486
213. Saydah S, Graubard B, Ballard-Barbash R, Berrigan D 2007 Insulin-like growth factors and subsequent risk of mortality in the United States. Am J Epidemiol 166:518-526
214. Missmer SA, Spiegelman D, Bertone-Johnson ER, Barbieri RL, Pollak MN, Hankinson SE 2006 Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period. Cancer Epidemiol Biomarkers Prev 15:972-978
215. Rinaldi S, Kaaks R, Zeleniuch-Jacquotte A, Arslan AA, Shore RE, Koenig KL, Dossus L, Riboli E, Stattin P, Lukanova A, Toniolo P 2005 Insulin-like growth factor-I, IGF binding protein-3, and breast cancer in young women: a comparison of risk estimates using different peptide assays. Cancer Epidemiol Biomarkers Prev 14:48-52
216. Berrigan D, Potischman N, Dodd KW, Nicar M, McQuillan G, Lavigne JA, Barrett JC, Ballard-Barbash R 2007 Serum levels of insulin-like growth factor-I and insulin-like growth factor-I binding protein-3: quality control for studies of stored serum. Cancer Epidemiol Biomarkers Prev 16:1017-1022
217. Deal C, Ma J, Wilkin F, Paquette J, Rozen F, Ge B, Hudson T, Stampfer M, Pollak M 2001 Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 86:1274-1280
218. Kao PC, Matheny Jr AP, Lang CA 1994 Insulin-like growth factor-I comparisons in healthy twin children. J Clin Endocrinol Metab 78:310-312
219. Harrela M, Koistinen H, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J, Toivanen L, Koskenvuo M, Leinonen P, Koistinen R, Seppälä M 1996 Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 98: 2612-2615
220. Schernhammer ES, Hankinson SE, Hunter DJ, Blouin MJ, Pollak MN 2003 Polymorphic variation at the - 202 locus in IGFBP3: influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. Int J Cancer 107:60-64
221. Tamimi RM, Cox DG, Kraft P, Pollak MN, Haiman CA, Cheng I, Freedman ML, Hankinson SE, Hunter DJ, Colditz GA 2007 Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study. Breast Cancer Res 9:R18
222. Cheng I, DeLellis Henderson K, Haiman CA, Kolonel LN, Henderson BE, Freedman ML, Le Marchand L 2007 Genetic determinants of circulating insulin-like growth factor (IGF)-I, IGF binding protein (BP)-1, and IGFBP-3 levels in a multiethnic population. J Clin Endocrinol Metab 92:3660-3666
223. Patel AV, Cheng I, Canzian F, Le Marchand L, Thun MJ, Berg CD, Buring J, Calle EE, Chanock S, Clavel-Chapelon F, Cox DG, Dorronsoro M, Dossus L, Haiman CA, Hankinson SE, Henderson BE, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Linseisen J, Lund E, Manjer J, McCarty C, Peeters PH, Pike MC, Pollak M, Riboli E, Stram DO, Tjonneland A, Travis RC, Trichopoulos D, Tumino R, Yeager M, Ziegler RG, Feigelson HS 2008 Breast and Prostate Cancer Cohort Consortium. IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS ONE 3:e2578